<DOC>
	<DOCNO>NCT01867697</DOCNO>
	<brief_summary>Nordic randomize phase II trial evaluate whether biweekly cetuximab alternate FOLFIRI mFOLFOX6 effective biweekly cetuximab continuously FOLFIRI patient potential resectable KRAS wildtype metastatic colorectal cancer . All patient randomize biweekly cetuximab 500 mg/m2 combination arm A ) FOLFIRI ( irinotecan 180 mg/m2 IV , leucovorin : 400 mg/m2 IV , 5FU bolus : 400 mg/m2 IV 46 hour 5FU infusion 2400 mg/m2 every 2 week ) arm B ) FOLFIRI alternate FOLFOX6 ( Oxaliplatin : 85 mg/m2 IV , leucovorin : 400 mg/m2 IV , 5FU bolus : 400 mg/m2 IV 46 hour 5FU infusion 2400 mg/m2 every 2 week ) . Primary objective : response rate ( RECIST 1.1 ) patient potential resectable KRAS wildtype metastatic colorectal cancer . Secondary objective : Resection rate , PFS , OS , Quality life , tolerability . Biomarker evaluation measure plasma biomarkers , Tumour block sequential serum plasma collect search marker may predict efficacy include respectability safety .</brief_summary>
	<brief_title>Nordic 8 - A Phase II Trial</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Histology stage : Histologically prove adenocarcinoma colon rectum At least 1 measurable metastatic disease manifestation accord RECIST criterion ( version 1.1 ) Potentially completely resectable potentially curable metastatic colorectal cancer determine local MDT conference require tumour shrinkage resection possible . The following definition indicative : 4 liver metastasis ( CRLeM ) without extrahepatic disease 2 lung metastasis ( CRLuM ) without hepatic extrahepatic disease 1 CRLeM determine `` potentially resectable '' ( location ) local MDT . 1 CRLuM determine local MDT potentially resectable ( location ) . Nonresectable primary disease resectable CRLeM CRLuM . KRAS BRAF status : Tumour tissue ( primary metastasis ) type wildtype KRAS AND wildtype BRAF General condition : age &gt; 18 year WHO performance status ≤ 1 expect survival &gt; 3 month sufficient bonemarrow function ( Hb ≥ 6.2 µmol/l/Hb &gt; 10 g/dl ANC ≥ 1.5 x 109/l , thrombocytes ≥ 100 x 109/l ) sufficient kidney liver function : total bilirubin ≤ 1.5 x upper normal limit , serum creatinine ≤ 1.25 x upper normal limit , ALAT ≤ 3 x upper normal limit ≤ 5 x upper normal limit liver metastases patient must sign inform declaration consent register ; must documentable accord national guideline Previous treatment : previous chemotherapy advanced/metastatic disease adjuvant chemotherapy unless complete 6 month registration previous treatment oxaliplatin irinotecan previous treatment cetuximab treatment EGFR History Inflammatory Bowel disease Severe uncontrolled cardiovascular disease , congestive heart failure NYHA III IV , unstable angina pectoris , history myocardial infarction within last twelve month , significant arrhythmia ) Any condition , accord treat physician 's judgement , could prevent planned medical/surgical treatment carry responsibly ( uncontrolled active infection , know hypersensitivity contraindication plan treatment . Pregnant breastfeed woman Patients fertile age want use reliable contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>